Clinical Trial Update: Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias [Phase 2]

View source ↗

Summary

This entry outlines a Phase 2 study evaluating imatinib (STI571) in patients with hypereosinophilic syndrome and eosinophilic leukemias, with the current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Leukemia
• Hypereosinophilic Syndrome
• Myeloproliferative Disorders

Drugs mentioned

• Imatinib (Gleevec) (imatinib)

Snippet

Sponsor: University of Bologna | Conditions: Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL) | Phase 2 | Status: UNKNOWN